I’ve never understood your strong interest in QLTI. Visudyne is a marginal drug, I’m unimpressed with the other stuff QLTI has done, and the stock has rarely if ever been dirt cheap. Maybe it’s a different story now; I haven’t looked closely since the merger.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”